Insmed Inc. Announces 12-Month OLE Study Data for Inhaled Treprostinil Palmitil

What Happened
Insmed Incorporated (INSM) filed a Form 8-K on July 16, 2026 under Regulation FD to announce 12-month safety and efficacy data from its ongoing open‑label extension (OLE) study of treprostinil palmitil inhalation powder in patients with pulmonary arterial hypertension (PAH). The company issued a press release and will host a conference call and live webcast to discuss the 12‑month results on July 16, 2026 at 8:00 a.m. Eastern Time. A slide presentation to be used on the call was also filed as an exhibit.

Key Details

• Date of filing/announcement: July 16, 2026 (Form 8-K, Regulation FD disclosure).
• Data reported: 12‑month safety and efficacy results from the ongoing OLE study of treprostinil palmitil inhalation powder in PAH patients.
• Investor events: Conference call and live webcast on July 16, 2026 at 8:00 a.m. ET; slide presentation available.
• Exhibits filed: Press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) attached to the 8-K.

Why It Matters
This disclosure gives investors access to one‑year clinical data for Insmed’s inhaled treprostinil palmitil program, which may inform assessment of the drug’s longer‑term safety and efficacy profile in PAH. The accompanying press release, slides, and live call provide the company’s direct presentation of results; investors can review those materials and listen to the webcast for more detail on the data and next steps.